Söndag 27 April | 11:47:19 Europe / Stockholm
Svenska | English
Investor Relations
Public Relations

Magle Chemoswed

Bifogade filer

Kursutveckling under dagen för detta pressmeddelande (SEK).

Likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Est. tid*
2026-02-27 08:30 Bokslutskommuniké 2025
2025-10-31 08:30 Kvartalsrapport 2025-Q3
2025-08-01 08:30 Kvartalsrapport 2025-Q2
2025-05-27 N/A X-dag ordinarie utdelning MAGLE 0.00 SEK
2025-05-26 N/A Årsstämma
2025-05-09 08:30 Kvartalsrapport 2025-Q1
2025-03-27 - Bokslutskommuniké 2024
2024-12-30 - Extra Bolagsstämma 2025
2024-10-24 - Kvartalsrapport 2024-Q3
2024-10-04 - Extra Bolagsstämma 2024
2024-07-18 - Kvartalsrapport 2024-Q2
2024-04-26 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2024-04-25 - Årsstämma
2024-04-18 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-07-18 - Kvartalsrapport 2023-Q2
2023-04-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2023-04-26 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-17 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2022-05-17 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-12-14 - Extra Bolagsstämma 2021
2021-11-16 - Kvartalsrapport 2021-Q3
2021-08-17 - Kvartalsrapport 2021-Q2
2021-05-14 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2021-04-18 - Årsstämma
2021-02-25 - Bokslutskommuniké 2020
2020-11-27 - Extra Bolagsstämma 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-14 - Kvartalsrapport 2020-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Magle Group bygger på strategiska förvärv som syftar till att driva tillväxt och diversifiera risker. Idag omfattar koncernen tre verksamhetsområden. Magle Chemoswed, en kontraktsutvecklings- och tillverkningsorganisation (CDMO). Magle PharmaCept, ett försäljnings- och marknadsföringsföretag för utveckling och direktförsäljning av koncernens medicintekniska produkter, och Magle Biopolymers A/S, en specialiserad tillverkningsorganisation för Dextran-teknologi.
Magle Chemoswed Holding Reports Financial Results For Third Quarter 2022
2022-11-09 08:29:00

Today, on 9 November 2022, Magle Chemoswed Holding AB (publ) has published its interim report for Q3 2022.

Q3 2022 KEY INDICATORS

  • Net sales amounted to 34.1MSEK (32.2)
  • EBITDA equalled 4.8 MSEK (4.9)
  • Operating profit (EBIT) is 1.4 MSEK (1.9)
  • Profit after tax amounted to 1.2 MSEK (1.5)
  • Earnings per share SEK 0,1 (0,1) per share

JAN-SEPT 2022 KEY INDICATORS

  • Net sales amounted to 99.7 MSEK (96.2)
  • EBITDA equalled 18.9 MSEK (12.5)
  • Operating profit (EBIT) is 8.9 MSEK (3.8)
  • Profit after tax amounted to 7.9 MSEK (3.0)
  • Earnings per share SEK 0,7 (0,3) per share

“Magle Group continued to deliver healthy year-on-year growth, both in terms of revenues and operating profit. The EBITDA margin is continuously in line with our financial target of 20%, and we remain well on track to deliver on our long-term strategic goals” says Justin Pierce, CEO of Magle Group.


The full report is available at https://maglegroup.com/financial-reports/

Contacts

Megi Medzmariashvili, Legal Counsel, phone +46 (0)76 164 33 12, megi.medzmariashvili@maglechemoswed.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and https://maglegroup.com/ and www.maglepharmacept.com

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-11-09 08:29 CET.

Attachments

Interim Report Q3 2022

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden